Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. 

Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Directorate General operational for Economy, Employment and Research

6K Venture Capital

Smedvig

Ifoghas Investments

Sambrinvest

Merieux Developpement

Meusinvest (Noshaq)

Kenneth Buckfire

Amyl Therapeutics

EnClear Therapies is a company focused on developing therapeutics for neurodegenerative diseases, including ALS.

EnClear Therapies

OptoCeutics is a biopharmaceutical company specializing in therapeutics for neurodegenerative diseases, with a focus on ALS treatment.

OptoCeutics

Denali Therapeutics is a biotechnology company dedicated to developing therapies for neurodegenerative diseases, including ALS.

Denali Therapeutics

Karyopharm Therapeutics is a biopharmaceutical company focused on developing therapies for various diseases, including potential treatments for ALS.

Karyopharm Therapeutics

Vistagen Therapeutics is a biopharmaceutical company engaged in the development of novel therapies for neurological and psychiatric disorders, potentially including ALS.

Vistagen Therapeutics

Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, aiming to improve the lives of patients and their families. The company's lead product candidate is designed to target the underlying causes of motor neuron disease and potentially other neurodegenerative conditions.

Amylyx Pharmaceuticals

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	May 15, 2024 12:05 PM	89bb8b21
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general
news basic	general
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:AMYLTX

Amylyx Pharmaceuticals